BNB Plus stock analysis
BNB Plus (UDJ1) Stock Price & Analysis
UDJ1 Stock Chart & Stats
- Day’s Range
- EUR 0.12 - EUR 0.15
- 52-Week Range
- EUR 0.02 - EUR 2.86
- Previous Close
- EUR 0.12
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 470.53K
- Enterprise Value
- EUR 2.64M
- Total Cash (Recent Filing)
- EUR 949.09K
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- 1.19
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound
TTM revenue growth of 198.5% shows materially improved commercial activity and provides a larger base for the company’s next phase. However, durability depends on converting that rebound into healthier margins; the growth is still a meaningful operating positive.
Low Leverage
Near-zero leverage reduces fixed financial obligations and refinancing pressure, while equity rising from about $2.3M to $12.5M provides a stronger capital base. This improves resilience and leaves more flexibility to fund operations or strategic initiatives, even though losses remain substantial.
Strategic Repositioning
The announced pivot targets infrastructure for financial institutions and enterprises, potentially moving the company toward recurring, production-scale blockchain and agentic-AI use cases. A secure, compliant deployment layer could broaden demand beyond passive digital-asset treasury activity if execution succeeds.
Bears Say
Extreme Losses
The severe operating and net losses show that the current revenue base is not supporting the company’s cost structure. Such deeply negative margins weaken internal funding capacity, reduce financial flexibility, and make sustained earnings improvement essential for the business model to become viable.
Cash Burn
Deeply negative operating and free cash flow indicate that the business is consuming substantial cash rather than funding itself. Unless cash generation improves, continued operations and strategic investment may require additional funding, potentially limiting management’s choices and increasing financing dependence.
Governance Concentration
The board changes increase the influence of investor-affiliated infrastructure entities over governance and capital strategy. Concentrated relationships can heighten execution and oversight risk during the strategic transition, particularly while the company is restructuring its business model and remains loss-making.
BNB Plus News
UDJ1 FAQ
What was BNB Plus’s price range in the past 12 months?
What is BNB Plus’s market cap?
When is BNB Plus’s upcoming earnings report date?
How were BNB Plus’s earnings last quarter?
Is BNB Plus overvalued?
Does BNB Plus pay dividends?
What is BNB Plus’s EPS estimate?
How many shares outstanding does BNB Plus have?
What happened to BNB Plus’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BNB Plus?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BNB Plus
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
- Sector
- Financial
- Industry
- Biotechnology
- CEO
- Clay D. Shorrock
- Employees
- 26
- Website
- www.bnbx.io
- Address
- 50 Health Sciences Drive, Stony Brook, NY, 11790, US
BNB Plus (UDJ1) Earnings & Revenues
UDJ1 Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted significant progress in revenue growth, operational efficiencies, and strategic focus on the LineaRx subsidiary. However, it also outlined challenges such as an increased net loss, a major business segment exit, and ongoing concerns about the company's financial stability. Despite these challenges, the strategic restructuring and new opportunities in the LineaRx segment suggest a cautiously optimistic outlook.
View all DE:UDJ1 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 1 | 10 |
| Technical Analysis | 5 | 1 | 2 |
| Moving Averages | 4 | 0 | 8 |









